Angiodynamics reports fiscal 2023 second quarter financial results; reaffirms guidance

Latham, n.y.--( business wire )--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2023, which ended november 30, 2022.
ANGO Ratings Summary
ANGO Quant Ranking